Meeting
2021 Genitourinary Cancers Symposium
Phase I study of entinostat in combination with enzalutamide for treatment of patients with castration-resistant prostate cancer.
Authors
Jianqing Lin
George Washington University Cancer Center, Washington, DC
Jianqing Lin , Jacob Matt Elkon , Brittany Ricart , Brooke Burgess , Erica Palmer , Robert S. Siegel , Yan Ma , Alejandro Villagra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03829930
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 96)
DOI
10.1200/JCO.2021.39.6_suppl.96
Abstract #
96
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.
First Author: Stephen V. Liu
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Pier VItale Nuzzo
Poster
2024 ASCO Genitourinary Cancers Symposium
The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guo Hongqian
Poster
2023 ASCO Genitourinary Cancers Symposium
Genomic, clinical characteristics, and treatment outcomes of patients with metastatic castration-sensitive prostate cancer with SPOP mutations: Analysis from the Kaiser Permanente Northern California Healthcare System.
First Author: Sachdev P. Thomas